Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAROMESTROCEL IS A PROPRIETARY, SCALABLE, ALLOGENEIC CELLULAR THERAPY BEING EVALUATED TO IMPROVE THE CLINICAL OUTCOMES OF CHILDREN WITH HLHS FULL ENROLLMENT ACHIEVED FOR PIVOTAL PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL AS A POTENTIAL ADJUNCT TREATMENT FOR HLHS, A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION ELPIS II TOP-LINE TRIAL RESULTS ARE ANTICIPATED IN THE THIRD QUARTER OF 2026 MIAMI, OCT. 27, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT JOSHUA M. HARE, MD, FACC, FAHA, LONGEVERON'S CO-FOUNDER, CHIEF SCIENCE OFFICER AND EXECUTIVE CHAIRMAN WAS INTERVIEWED ON NATIONAL PUBLIC RADIO'S (NPR) BIOTECH NATION WITH DR. MOIRA GUNN.

LONGEVERON CO-FOUNDER AND CHIEF SCIENCE OFFICER DR. JOSHUA HARE INTERVIEWED ON NPR'S BIOTECH NATION DISCUSSING POTENTIAL BREAKTHROUGH STEM CELL THERAPY FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS), A RARE PEDIATRIC CONGENITAL HEART DEFECT

MIAMI, OCT. 06, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE. LONGEVERON MANAGEMENT WILL HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE CONFERENCE TO BE HELD OCTOBER 9, 2025 IN NEW YORK.

LONGEVERON TO PARTICIPATE IN THE 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE

EXPLORING POTENTIAL PARTNERSHIPS AND STRATEGIC OPPORTUNITIES FOR THE COMPANY'S STEM CELL THERAPY PROGRAM IN ALZHEIMER'S DISEASE ALZHEIMER'S DISEASE DEVELOPMENT PROGRAM WITH POSITIVE DATA IN SUCCESSFUL PHASE 1 AND PHASE 2A CLINICAL TRIALS CLEAR REGULATORY PATHWAY FOLLOWING POSITIVE TYPE B MEETING WITH U.S. FDA FDA HAS GRANTED LAROMESTROCEL BOTH REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION AND FAST TRACK DESIGNATION FOR THE TREATMENT OF MILD ALZHEIMER'S DISEASE MIAMI, SEPT. 22, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE ALLIANCE FOR REGENERATIVE MEDICINE'S CELL & GENE MEETING ON THE MESA TAKING PLACE OCTOBER 6-8, 2025 IN PHOENIX, ARIZONA.

LONGEVERON TO ATTEND ALLIANCE FOR REGENERATIVE MEDICINE'S CELL & GENE MEETING ON THE MESA

THAN POWELL, CHIEF BUSINESS OFFICER AND HEAD OF BUSINESS DEVELOPMENT, APPOINTED INTERIM CEO DR. JOSHUA HARE, CO-FOUNDER AND CHIEF SCIENCE OFFICER, APPOINTED EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS WA'EL HASHAD TO STEP DOWN AS CEO AND BOARD MEMBER NATIONAL SEARCH TO OCCUR FOR PERMANENT CEO MIAMI, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED KEY LEADERSHIP UPDATES.

LONGEVERON ANNOUNCES KEY LEADERSHIP UPDATES

MIAMI, AUG. 20, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE TAKING PLACE SEPTEMBER 8-10, 2025 IN NEW YORK CITY.

LONGEVERON TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

MIAMI, AUG. 13, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE.

LONGEVERON ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MIAMI, AUG. 11, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) (LONGEVERON OR COMPANY), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED PUBLIC OFFERING OF 5,882,354 OF THE COMPANY'S CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), TOGETHER WITH SHORT-TERM WARRANTS TO PURCHASE UP TO 14,705,885 SHARES OF CLASS A COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.85 PER SHARE OF CLASS A COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING SHORT-TERM WARRANTS. THE SHORT-TERM WARRANTS HAVE AN EXERCISE PRICE OF $0.85 PER SHARE AND ARE IMMEDIATELY EXERCISABLE UPON ISSUANCE FOR A PERIOD OF TWENTY-FOUR MONTHS FOLLOWING THE DATE OF ISSUANCE.

LONGEVERON ANNOUNCES CLOSING OF UP TO $17.5 MILLION PUBLIC OFFERING

MIAMI, AUG. 08, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) (LONGEVERON OR COMPANY), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THE PRICING OF A PUBLIC OFFERING OF 5,882,354 OF THE COMPANY'S CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), TOGETHER WITH SHORT-TERM WARRANTS TO PURCHASE UP TO 14,705,885 SHARES OF CLASS A COMMON STOCK AT A COMBINED PUBLIC OFFERING PRICE OF $0.85 PER SHARE OF CLASS A COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) AND ACCOMPANYING SHORT-TERM WARRANTS. THE SHORT-TERM WARRANTS WILL HAVE AN EXERCISE PRICE OF $0.85 PER SHARE AND WILL BE IMMEDIATELY EXERCISABLE UPON ISSUANCE FOR A PERIOD OF TWENTY-FOUR MONTHS FOLLOWING THE DATE OF ISSUANCE.

LONGEVERON ANNOUNCES UP TO $17.5 MILLION PUBLIC OFFERING

MIAMI, AUG. 05, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON WEDNESDAY, AUGUST 13, 2025 AFTER THE U.S. FINANCIAL MARKETS CLOSE. THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST THE SAME DAY AT 4:30 P.M.

LONGEVERON TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 13, 2025

LONGEVERON HAS LICENSED ISSUED US PATENT 12,168,028 B2 , ENTITLED METHODS FOR OBTAINING CARDIOMYOGENIC PRECURSOR CELLS FROM THE UNIVERSITY OF MIAMI NEW PATENT PROTECTS A METHOD TO DERIVE GHRH-RECEPTOR+ CARDIOMYOGENIC CELLS FROM PLURIPOTENT STEM CELLS (PSCS) NEW TECHNOLOGY SUBSTANTIALLY ADVANCES LONGEVERON'S REPERTOIRE OF STEM CELL THERAPY TECHNOLOGIES OPPORTUNITY TO EXPAND PIPELINE IN CARDIOVASCULAR, RARE AND PEDIATRIC DISEASE AREAS MIAMI, JULY 21, 2025 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING, RARE PEDIATRIC, AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT HAS LICENSED AN ISSUED US PATENT (12,168,028 B2) FOR A STEM CELL TECHNOLOGY FROM THE UNIVERSITY OF MIAMI. THE COMPOSITION OF MATTER PATENT PROTECTS UNIQUE INDUCED PLURIPOTENT DERIVED CARDIOMYOGENIC CELLS THAT HAVE WIDESPREAD THERAPEUTIC INDICATIONS FOR HEART DISEASES.

Longeveron Inc.

LGVN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Longeveron Inc.

LGVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LGVN